In today’s briefing:
- Samsung SDI: Announces a 2 Trillion Won Rights Offering Capital Raise
- Bama Tea Pre-IPO – Fourth Attempt to Go Public
- Bluestone Jewellery and Lifestyle Pre-IPO – Strong Growth but with Cash Flow Struggles
- DN Solutions IPO Preview
- Duality Biotherapeutics (映恩生物) Pre-IPO: PHIP Updates Show Slight Improvements
Samsung SDI: Announces a 2 Trillion Won Rights Offering Capital Raise
- On 14 March, Samsung SDI (006400 KS) announced a 2 trillion won (US$1.4 billion) rights offering capital raise plan.
- Samsung SDI’s 2 trillion won capital raise is likely to have a near-term negative impact on the company’s share price.
- We are negative on Samsung SDI’s rights offering capital raise mainly due to shares dilution. We also remain concerned that weak demand for EVs globally could last longer.
Bama Tea Pre-IPO – Fourth Attempt to Go Public
- Bama Tea (BT) is looking to raise at least US$100m in its upcoming Hong Kong IPO.
- BT mainly grew through franchising. Its broad portfolio boosts market reach. A shift to online sales and stable tea prices may improve gross margins.
- BT needs capital for expansion but faces challenges: a fragmented, slow-growing industry, declining franchise earnings, weak 9M24 tea-leaf sales, supplier/customer concentration, and this being BT’s fourth attempt at going public.
Bluestone Jewellery and Lifestyle Pre-IPO – Strong Growth but with Cash Flow Struggles
- Bluestone Jewellery and Lifestyle Ltd Ltd (BJL) (0124165D IN)(BJL) is planning to raise about US$118m in its upcoming India IPO.
- BJL offers contemporary lifestyle diamond, gold, platinum, and studded jewellery under its flagship brand.
- It is a digital-first direct-to-consumer (DTC) brand and is the second largest digital-first omni-channel jewellery brand in India in terms of revenue for FY24, as per RedSeer Report.
DN Solutions IPO Preview
- DN Solutions is getting ready to complete its IPO in Korea in May 2025. The IPO price range is from 65,000 won to 89,700 won.
- The book building for the institutional investors will last from 22 to 28 April. The expected IPO offering amount is from 1.14 trillion won to 1.57 trillion won.
- The IPO price range is based on DN Solutions’ net profit of 317.4 billion won, P/E of 25.2x, and IPO discount rates of 29.1% to 48.6%.
Duality Biotherapeutics (映恩生物) Pre-IPO: PHIP Updates Show Slight Improvements
- Duality Biotherapeutics, a China-based clinical-stage biotechnology company, plans to raise up to US$300m via a Hong Kong listing.
- The company has passed the hearing for the listing and filed a new version of the prospectus.
- We look at the difference between previous filing and current filing.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
Unlock all research summaries